Clinical trial · Observational
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis
NCT00638391CI-TRIAL-00001357Ax-003completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastrozole | Drug | Anastrozole | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- all patients treated with Anastrozole
- interventionNames
- Drug: Anastrozole
Primary outcomes (1)
- measure
- evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions
- timeFrame
- 12 months
Secondary outcomes (2)
- measure
- description of population treated with anastrozole
- timeFrame
- 12 months
- measure
- further information about the change of specific laboratory parameters
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women with early hormone receptor positive breast cancer/no metastasis Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.